Kidney, cardiovascular and all-cause mortality outcomes of semaglutide with and without baseline MRA use in type 2 diabetes and CKD: a FLOW trial analysis

FLOW Trial Committees and Investigators

OriginalsprogEngelsk
ArtikelnummerLBA 21
TidsskriftDiabetologia
Vol/bind67
Udgave nummerSuppl. 1
ISSN0012-186X
DOI
StatusUdgivet - 2024
Begivenhed60th EASD Annual Meeting: EASD 2024
- Madrid, Spanien
Varighed: 9 sep. 202413 sep. 2024

Konference

Konference60th EASD Annual Meeting: EASD 2024
Land/OmrådeSpanien
ByMadrid
Periode09/09/202413/09/2024

Citationsformater